Immunotherapy may become new first line treatment in some metastatic colorectal cancers
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich. (1) The drug combination shrank tumours and had beneficial effects on survival in patients with microsatellite instabiliy (MSI)-high metastatic colorectal cancer.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Immunotherapy | Pharmaceuticals | Politics | Yervoy